Total Payments
$208,734
2024 Payments
$84.98
Companies
17
Transactions
66
Payment Breakdown by Category
Research$206,393 (98.9%)
Food & Beverage$1,237 (0.6%)
Travel$1,105 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $206,393 | 25 | 98.9% |
| Food and Beverage | $1,237 | 36 | 0.6% |
| Travel and Lodging | $1,105 | 5 | 0.5% |
Payments by Type
Research
$206,393
25 transactions
General
$2,342
41 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Arbor Pharmaceuticals, Inc. | $171,129 | 8 | $0 (2019) |
| Purdue Pharma L.P. | $32,732 | 11 | $0 (2022) |
| Allergan Inc. | $2,564 | 7 | $0 (2018) |
| Merck Sharp & Dohme LLC | $1,036 | 8 | $0 (2023) |
| Janssen Research & Development, LLC | $762.43 | 11 | $0 (2017) |
| Takeda Pharmaceuticals U.S.A., Inc. | $119.80 | 1 | $0 (2018) |
| Alkermes, Inc. | $108.01 | 5 | $0 (2021) |
| Otsuka America Pharmaceutical, Inc. | $69.54 | 4 | $0 (2020) |
| Janssen Pharmaceuticals, Inc | $50.66 | 2 | $0 (2023) |
| Indivior Inc. | $40.93 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $84.98 | 5 | Eisai Inc. ($22.21) |
| 2023 | $1,086 | 10 | Merck Sharp & Dohme LLC ($1,036) |
| 2022 | $9,306 | 2 | Purdue Pharma L.P. ($9,306) |
| 2021 | $23,468 | 11 | Purdue Pharma L.P. ($23,426) |
| 2020 | $65.52 | 3 | Alkermes, Inc. ($41.43) |
| 2019 | $171,166 | 10 | Arbor Pharmaceuticals, Inc. ($171,129) |
| 2018 | $227.70 | 6 | Takeda Pharmaceuticals U.S.A., Inc. ($119.80) |
| 2017 | $3,330 | 19 | Allergan Inc. ($2,532) |
All Payment Transactions
66 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $16.21 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/27/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $13.45 | General |
| Category: Neuropsychiatry | ||||||
| 11/15/2024 | Almatica Pharma LLC | LOREEV XR (Drug) | Food and Beverage | In-kind items and services | $16.25 | General |
| Category: ANTI-ANXIETY | ||||||
| 06/18/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $22.21 | General |
| Category: Oncology | ||||||
| 02/08/2024 | Braeburn Inc. | BRIXADI (Drug) | Food and Beverage | In-kind items and services | $16.86 | General |
| Category: Opioid Use Disorder | ||||||
| 04/13/2023 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $20.20 | General |
| Category: Neuroscience | ||||||
| 01/27/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $75.28 | General |
| Category: NEUROSCIENCE | ||||||
| 01/27/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $49.39 | General |
| Category: NEUROSCIENCE | ||||||
| 01/27/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $49.39 | General |
| Category: NEUROSCIENCE | ||||||
| 01/27/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $34.98 | General |
| Category: NEUROSCIENCE | ||||||
| 01/26/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $301.00 | General |
| Category: NEUROSCIENCE | ||||||
| 01/26/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $234.90 | General |
| Category: NEUROSCIENCE | ||||||
| 01/26/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $167.39 | General |
| Category: NEUROSCIENCE | ||||||
| 01/26/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $123.47 | General |
| Category: NEUROSCIENCE | ||||||
| 01/13/2023 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug), INVEGA TRINZA | Food and Beverage | In-kind items and services | $30.46 | General |
| Category: Neuroscience | ||||||
| 07/01/2022 | Purdue Pharma L.P. | — | — | Cash or cash equivalent | $6,703.00 | Research |
| Study: Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States | ||||||
| 06/20/2022 | Purdue Pharma L.P. | ADHANSIA XR (Drug) | — | Cash or cash equivalent | $2,602.90 | Research |
| Study: Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States • Category: PRESCRIPTION STIMULANT | ||||||
| 12/21/2021 | Purdue Pharma L.P. | ADHANSIA XR (Drug) | — | Cash or cash equivalent | $525.60 | Research |
| Study: Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States • Category: PRESCRIPTION STIMULANT | ||||||
| 12/20/2021 | Purdue Pharma L.P. | ADHANSIA XR (Drug) | — | Cash or cash equivalent | $932.40 | Research |
| Study: Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States • Category: PRESCRIPTION STIMULANT | ||||||
| 12/01/2021 | Purdue Pharma L.P. | ADHANSIA XR (Drug) | — | Cash or cash equivalent | $991.80 | Research |
| Study: Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States • Category: PRESCRIPTION STIMULANT | ||||||
| 10/19/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $18.46 | General |
| Category: NEUROSCIENCE | ||||||
| 10/04/2021 | Purdue Pharma L.P. | ADHANSIA XR (Drug) | — | Cash or cash equivalent | $525.60 | Research |
| Study: Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States • Category: PRESCRIPTION STIMULANT | ||||||
| 09/01/2021 | Purdue Pharma L.P. | ADHANSIA XR (Drug) | — | Cash or cash equivalent | $1,964.70 | Research |
| Study: Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States • Category: PRESCRIPTION STIMULANT | ||||||
| 08/06/2021 | Purdue Pharma L.P. | ADHANSIA XR (Drug) | — | Cash or cash equivalent | $5,966.10 | Research |
| Study: Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States • Category: PRESCRIPTION STIMULANT | ||||||
| 06/02/2021 | Purdue Pharma L.P. | ADHANSIA XR (Drug) | — | Cash or cash equivalent | $762.30 | Research |
| Study: Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States • Category: PRESCRIPTION STIMULANT | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Adult Attention Deficit Hyperactivity Disorder ADHD Study With Amphetamine Sulfate | Arbor Pharmaceuticals, Inc. | $171,129 | 8 |
| Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States | Purdue Pharma L.P. | $32,732 | 11 |
| A Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Rapastinel for Rapid Treatment of Symptoms of Depression and Suicidality in Adult Patients with Major Depressive Disorder | Allergan Inc. | $2,532 | 6 |
About Dr. Zaheer Aslam, MD
Dr. Zaheer Aslam, MD is a Psychiatry healthcare provider based in Fort Myers, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1609950468.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Zaheer Aslam, MD has received a total of $208,734 in payments from pharmaceutical and medical device companies, with $84.98 received in 2024. These payments were reported across 66 transactions from 17 companies. The most common payment nature is "" ($206,393).
Ad
Practice Information
- Specialty Psychiatry
- Other Specialties Psychiatry, Addiction Psychiatry
- Location Fort Myers, FL
- Active Since 10/25/2006
- Last Updated 09/25/2019
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1609950468
Products in Payments
- AR19 (Drug) $171,129
- ADHANSIA XR (Drug) $26,029
- ABILIFY MAINTENA (Drug) $45.45
- VIVITROL (Drug) $42.92
- Vivitrol (Drug) $41.43
- SUBLOCADE (Drug) $40.93
- INVEGA SUSTENNA (Drug) $30.46
- REXULTI (Drug) $24.09
- Vivitrol 380 mg (Drug) $23.66
- Lenvima (Drug) $22.21
- SPRAVATO (Drug) $20.20
- LATUDA (Drug) $19.05
- VRAYLAR (Drug) $18.46
- BRIXADI (Drug) $16.86
- LOREEV XR (Drug) $16.25
- COBENFY (Drug) $16.21
- INGREZZA (Drug) $13.45
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Fort Myers
Dr. Steven Machlin, M.d, M.D
Psychiatry — Payments: $13,274
Psychiatry $13,274
Dr. Sanjeev Singh, M.d, M.D
Psychiatry — Payments: $11,880
Psychiatry $11,880
Eric Raab, D.o, D.O
Psychiatry — Payments: $8,615
Psychiatry $8,615
Dr. Fred Jean, Md, MD
Psychiatry — Payments: $5,931
Psychiatry $5,931
Asaf Aleem, Md, MD
Psychiatry — Payments: $5,720
Psychiatry $5,720
Dr. Staci Knickrehm, Do, DO
Psychiatry — Payments: $4,217
Psychiatry $4,217